IMUNON

IMNNPhase 3

IMUNON is focused on developing new medicines that harness the body's immune system using DNA-based technology. The company's core platforms, TheraPlas™ for immuno-oncology and PlaCCine for infectious disease vaccines, aim to generate potent, targeted immune responses. With a seasoned leadership team and a pipeline targeting significant unmet medical needs, IMUNON is advancing its clinical programs while exploring broader applications for its synthetic DNA delivery systems.

Market Cap

$9.8M

Focus

Small Molecules

IMNN · Stock Price

USD 2.8768.74 (-95.99%)

Historical price data

AI Company Overview

Technology Platform

Proprietary non-viral DNA delivery platforms (TheraPlas™ for immunotherapies and PlaCCine for vaccines) that use synthetic chemistry to instruct the body's cells to produce therapeutic proteins, generating targeted immune responses.

Pipeline Snapshot

16 drugs in pipeline, 3 in Phase 3

Drug	Indication	Stage
ThermoDox + 5% Dextrose Solution	Hepatocellular Carcinoma	Phase 3
ThermoDox + Dummy infusion	Hepatocellular Carcinoma	Phase 3
IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer) + Pacli...	Epithelial Ovarian Cancer	Phase 3
ThermoDox (Thermally Sensitive Liposomal Doxorubicin)	Breast Cancer	Phase 2
High Intensity Focused Ultrasound (HIFU) in combination with ThermoDox	Painful Bone Metastases	Phase 2

Opportunities

Significant opportunities exist in expanding the TheraPlas™ platform beyond ovarian cancer to other solid tumors and in advancing the PlaCCine platform into clinical trials for infectious diseases.

Success in current clinical studies could attract strategic partnerships or licensing deals, providing non-dilutive funding and validation.

Risk Factors

Key risks include clinical trial failure of the lead candidate, financial constraints common to micro-cap biotechs, intense competition in both oncology and vaccine spaces, and the technological challenge of demonstrating platform superiority over established and emerging modalities.

Competitive Landscape

IMUNON competes with numerous companies in DNA/gene therapy and nucleic acid vaccines. Differentiation hinges on its proprietary non-viral delivery system's ability to provide targeted, durable immune activation with a favorable safety profile, competing against viral vectors, mRNA technologies, and other immunotherapies.